MHS-MCG: Mason Heart Study With MCG

Sponsor
Genetesis Inc. (Industry)
Overall Status
Recruiting
CT.gov ID
NCT04732975
Collaborator
(none)
250
1
17.5
14.2

Study Details

Study Description

Brief Summary

Heart disease is the number one cause of death in the United States, with over 650,000 deaths in 2019 alone. Many healthy individuals possess key risk factors for heart disease which include but are not limited to high blood pressure, high cholesterol, family history of heart disease, and diabetes. The Mason Heart Study-MCG (MHS-MCG) registry is designed to collect magnetocardiography (MCG) scans on a select group of healthy volunteers who work for the city of Mason, OH, with and without cardiac symptoms, illnesses, and/or risk factors. CardioFlux is used as a noninvasive MCG tool that analyzes and records the magnetic fields of the heart to detect various forms of heart disease. There will be a 12-month duration of the study where we propose to collect screening data from approximately 250 volunteers who present to the Genetesis facility for a 5-minute CardioFlux MCG scan. The volunteers will be contacted at intervals over a 1-year period for follow-up data and may choose whether or not they would like to provide follow-up data or participate in another scan.

Condition or Disease Intervention/Treatment Phase
  • Device: CardioFlux

Study Design

Study Type:
Observational
Anticipated Enrollment :
250 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
Mason Heart Study With Magnetocardiography
Actual Study Start Date :
Dec 14, 2020
Anticipated Primary Completion Date :
Jun 1, 2022
Anticipated Study Completion Date :
Jun 1, 2022

Outcome Measures

Primary Outcome Measures

  1. specificity and accuracy statistics [6 months]

    analyzing the specificity and accuracy of CardioFlux

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  1. ≥ 18 years of age at the time of enrollment.
Exclusion Criteria:
  1. < 18 years of age

  2. Patients unable to fit into device

  3. Non-ambulatory patients

  4. Positive response on CardioFlux Pre-Screening Form

  5. Patients with claustrophobia or unable to lie supine for 5 minutes

  6. Pregnant women

  7. Poor candidate for follow-up (e.g. no access to phone)

  8. Prisoners

Contacts and Locations

Locations

Site City State Country Postal Code
1 Genetesis Facility Mason Ohio United States 45040

Sponsors and Collaborators

  • Genetesis Inc.

Investigators

  • Principal Investigator: Anthony Senagore, M.D., Genetesis Inc.

Study Documents (Full-Text)

None provided.

More Information

Additional Information:

Publications

Responsible Party:
Genetesis Inc.
ClinicalTrials.gov Identifier:
NCT04732975
Other Study ID Numbers:
  • 1000-3
First Posted:
Feb 1, 2021
Last Update Posted:
Sep 16, 2021
Last Verified:
Sep 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
Yes
Product Manufactured in and Exported from the U.S.:
No
Keywords provided by Genetesis Inc.

Study Results

No Results Posted as of Sep 16, 2021